TABLE 1 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 4 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 8 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL ORAL IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL INTRAVENOUS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL TOPICAL IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 25 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 26 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 27 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 28 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 30 GLOBAL THERAPY IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 32 GLOBAL ADULTS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 GLOBAL PEDIATRIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 35 GLOBAL FEMALE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 GLOBAL MALE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 38 LOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 GLOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 40 GLOBAL TRANSPLANT CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 GLOBAL INSTITUTES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 42 GLOBAL SPECIALITY CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 44 GLOBAL DIRECT TENDER IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 47 GLOBAL OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 48 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA IMMUNOSUPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 61 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 NORTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 64 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 65 NORTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 66 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 67 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 68 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 71 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 72 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 73 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 74 NORTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 75 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 76 NORTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 77 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 79 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 80 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 81 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 82 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 86 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 87 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 88 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 U.S. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 91 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 92 U.S. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 93 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 94 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 95 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 98 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 99 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 100 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 101 U.S. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 102 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 103 U.S. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 104 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 105 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 106 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 107 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 108 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 109 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 113 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 114 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 115 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 CANADA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 118 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 119 CANADA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 120 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 121 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 122 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 125 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 126 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 127 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 128 CANADA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 129 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 130 CANADA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 131 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 132 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 133 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 134 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 135 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 136 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 140 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 141 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 142 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 143 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 144 MEXICO ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 145 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 146 MEXICO IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 147 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 148 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 149 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 151 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 152 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 153 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 154 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 155 MEXICO HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 156 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 157 MEXICO RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 158 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 159 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 160 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 161 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 162 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 163 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 164 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 167 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 168 EUROPE CORTICOSTEROIDS GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 169 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 170 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 EUROPE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 173 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 174 EUROPE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 175 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 176 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 177 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 178 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 180 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 181 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 182 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 183 EUROPE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 184 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 185 EUROPE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 186 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 187 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 188 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 189 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 190 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 191 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 193 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 194 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 195 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 196 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 197 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 198 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 GERMANY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 200 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 201 GERMANY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 202 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 203 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 204 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 207 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 208 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 209 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 210 GERMANY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 211 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 212 GERMANY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 213 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 214 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 215 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 216 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 217 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 218 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 221 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 222 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 223 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 224 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 225 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 FRANCE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 227 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 228 FRANCE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 229 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 230 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 231 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 234 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 235 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 236 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 237 FRANCE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 238 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 239 FRANCE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 240 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 241 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 242 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 243 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 244 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 245 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 246 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 247 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 248 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 249 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 250 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 251 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 252 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 ITALY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 254 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 255 ITALY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 256 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 257 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 258 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 259 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 261 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 262 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 263 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 264 ITALY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 265 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 266 ITALY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 267 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 268 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 269 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 270 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 271 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 272 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 274 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 276 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 277 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 278 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 280 U.K. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 281 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 282 U.K. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 283 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 284 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 285 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 286 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 287 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 288 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 289 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 290 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 291 U.K. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 292 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 293 U.K. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 294 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 295 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 296 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 297 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 298 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 299 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 300 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 302 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 303 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 304 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 305 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 306 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 307 SPAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 308 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 309 SPAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 310 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 311 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 312 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 314 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 315 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 316 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 317 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 318 SPAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 319 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 320 SPAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 321 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 322 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 323 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 324 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 325 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 326 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 328 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 329 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 330 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 331 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 332 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 334 BELGIUM ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 335 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 336 BELGIUM IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 337 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 338 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 339 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 341 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 342 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 343 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 344 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 345 BELGIUM HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 346 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 347 BELGIUM RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 348 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 349 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 350 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 351 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 352 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 353 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 354 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 355 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 356 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 357 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 358 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 359 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 360 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 361 RUSSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 362 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 363 RUSSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 364 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 365 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 366 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 367 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 368 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 369 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 370 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 371 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 372 RUSSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 373 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 374 RUSSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 375 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 376 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 377 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 378 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 379 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 380 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 381 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 382 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 383 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 384 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 385 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 386 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 387 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 388 SWITZERLAND ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 389 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 390 SWITZERLAND IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 391 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 392 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 393 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 394 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 395 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 396 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 397 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 398 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 399 SWITZERLAND HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 400 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 401 SWITZERLAND RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 402 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 403 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 404 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 405 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 406 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 407 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 408 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 409 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 410 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 411 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 412 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 413 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 414 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 415 DENMARK ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 416 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 417 DENMARK IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 418 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 419 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 420 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 421 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 422 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 423 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 424 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 425 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 426 DENMARK HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 427 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 428 DENMARK RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 429 REST OF EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 430 ASIA-PACIFIC GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 431 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 432 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 433 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 434 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 435 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 436 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 437 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 438 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 439 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 440 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 441 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 442 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 443 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 444 ASIA-PACIFIC ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 445 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 446 ASIA-PACIFIC IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 447 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 448 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 449 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 450 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 451 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 452 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 453 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 454 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 455 ASIA-PACIFIC HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 456 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 457 ASIA-PACIFIC RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 458 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 459 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 460 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 461 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 462 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 463 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 464 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 465 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 466 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 467 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 468 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 469 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 470 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 471 JAPAN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 472 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 473 JAPAN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 474 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 475 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 476 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 477 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 478 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 479 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 480 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 481 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 482 JAPAN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 483 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 484 JAPAN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 485 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 486 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 487 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 488 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 489 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 490 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 491 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 492 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 493 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 494 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 495 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 496 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 497 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 498 CHINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 499 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 500 CHINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 501 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 502 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 503 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 504 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 505 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 506 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 507 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 508 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 509 CHINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 510 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 511 CHINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 512 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 513 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 514 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 515 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 516 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 517 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 518 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 519 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 520 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 521 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 522 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 523 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 524 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 525 AUSTRALIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 526 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 527 AUSTRALIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 528 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 529 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 530 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 531 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 532 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 533 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 534 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 535 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 536 AUSTRALIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 537 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 538 AUSTRALIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 539 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 540 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 541 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 542 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 543 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 544 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 545 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 546 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 547 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 548 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 549 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 550 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 551 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 552 SOUTH KOREA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 553 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 554 SOUTH KOREA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 555 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 556 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 557 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 558 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 559 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 560 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 561 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 562 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 563 SOUTH KOREA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 564 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 565 SOUTH KOREA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 566 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 567 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 568 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 569 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 570 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 571 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 572 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 573 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 574 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 575 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 576 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 577 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 578 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 579 INDIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 580 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 581 INDIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 582 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 583 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 584 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 585 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 586 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 587 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 588 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 589 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 590 INDIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 591 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 592 INDIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 593 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 594 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 595 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 596 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 597 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 598 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 599 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 600 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 601 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 602 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 603 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 604 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 605 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 606 MALAYSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 607 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 608 MALAYSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 609 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 610 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 611 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 612 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 613 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 614 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 615 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 616 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 617 MALAYSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 618 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 619 MALAYSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 620 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 621 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 622 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 623 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 624 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 625 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 626 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 627 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 628 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 629 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 630 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 631 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 632 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 633 SINGAPORE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 634 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 635 SINGAPORE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 636 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 637 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 638 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 639 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 640 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 641 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 642 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 643 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 644 SINGAPORE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 645 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 646 SINGAPORE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 647 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 648 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 649 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 650 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 651 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 652 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 653 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 654 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 655 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 656 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 657 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 658 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 659 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 660 PHILIPPINES ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 661 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 662 PHILIPPINES IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 663 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 664 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 665 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 666 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 667 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 668 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 669 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 670 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 671 PHILIPPINES HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 672 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 673 PHILIPPINES RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 674 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 675 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 676 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 677 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 678 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 679 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 680 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 681 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 682 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 683 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 684 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 685 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 686 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 687 INDONESIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 688 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 689 INDONESIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 690 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 691 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 692 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 693 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 694 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 695 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 696 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 697 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 698 INDONESIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 699 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 700 INDONESIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 701 REST OF ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 702 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 703 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 704 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 705 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 706 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 707 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 708 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 709 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 710 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 711 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 712 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 713 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 714 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 715 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 716 MIDDLE EAST AND AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 717 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 718 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 719 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 720 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 721 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 722 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 723 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 724 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 725 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 726 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 727 MIDDLE EAST AND AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 728 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 729 MIDDLE EAST AND AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 730 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 731 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 732 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 733 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 734 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 735 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 736 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 737 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 738 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 739 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 740 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 741 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 742 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 743 SOUTH AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 744 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 745 SOUTH AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 746 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 747 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 748 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 749 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 750 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 751 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 752 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 753 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 754 SOUTH AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 755 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 756 SOUTH AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 757 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 758 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 759 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 760 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 761 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 762 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 763 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 764 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 765 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 766 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 767 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 768 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 769 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 770 SAUDI ARABIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 771 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 772 SAUDI ARABIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 773 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 774 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 775 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 776 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 777 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 778 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 779 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 780 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 781 SAUDI ARABIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 782 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 783 SAUDI ARABIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 784 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 785 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 786 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 787 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 788 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 789 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 790 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 791 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 792 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 793 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 794 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 795 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 796 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 797 U.A.E. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 798 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 799 U.A.E. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 800 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 801 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 802 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 803 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 804 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 805 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 806 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 807 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 808 U.A.E. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 809 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 810 U.A.E. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 811 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 812 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 813 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 814 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 815 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 816 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 817 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 818 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 819 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 820 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 821 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 822 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 823 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 824 KUWAIT ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 825 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 826 KUWAIT IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 827 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 828 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 829 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 830 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 831 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 832 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 833 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 834 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 835 KUWAIT HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 836 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 837 KUWAIT RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 838 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 839 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 840 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 841 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 842 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 843 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 844 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 845 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 846 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 847 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 848 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 849 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 850 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 851 BAHRAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 852 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 853 BAHRAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 854 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 855 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 856 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 857 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 858 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 859 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 860 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 861 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 862 BAHRAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 863 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 864 BAHRAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 865 REST OF MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 866 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 867 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 868 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 869 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 870 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 871 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 872 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 873 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 874 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 875 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 876 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 877 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 878 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 879 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 880 SOUTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 881 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 882 SOUTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 883 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 884 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 885 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 886 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 887 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 888 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 889 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 890 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 891 SOUTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 892 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 893 SOUTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 894 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 895 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 896 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 897 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 898 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 899 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 900 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 901 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 902 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 903 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 904 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 905 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 906 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 907 BRAZIL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 908 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 909 BRAZIL IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 910 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 911 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 912 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 913 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 914 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 915 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 916 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 917 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 918 BRAZIL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 919 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 920 BRAZIL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 921 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 922 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 923 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 924 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 925 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 926 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 927 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 928 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 929 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 930 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 931 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 932 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 933 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 934 ARGENTINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 935 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 936 ARGENTINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 937 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 938 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 939 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 940 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 941 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 942 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 943 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 944 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 945 ARGENTINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 946 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 947 ARGENTINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 948 REST OF SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)